Appili readies antibiotic bridging study

Appili readies antibiotic bridging study

Closely-held Appili Therapeutics plans to begin late in the current quarter a Phase 1 bridging, or bioequivalence, study of its lead anti-infective, ATI-1501, a reformulated, taste-masked liquid suspension of metronidazole, targeting anaerobic bacterial infections, including Clostridium difficile.

Read More

PureTech targeting dysfunctions in brain, gut, immune system

PureTech targeting dysfunctions in brain, gut, immune system

With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious diseases caused by dysfunctions in the brain, gut and immune system.

Read More

In conversation with John Gannon of TempTraq

In conversation with John Gannon of TempTraq

As president and CEO of closely-held Blue Spark Technologies and co-inventor of its newest product, TempTraq, John Gannon’s career has stretched from the aerospace industry to Wall Street, culminating in 2011 with this developer of thin, flexible printed batteries built on IP from Eveready Battery, now Energizer. He has worked as an engineer in GE’s Astro-Space division and in currency derivatives with Merrill Lynch in New York and Barclays Capital in London, drawing on his background in mathematics, physics, engineering and business administration. In this interview with BioTuesdays.com, Mr. Gannon discusses Blue Sparks’ TempTraq medical device, a wireless, wearable patch that continuously monitors body temperature for the hospital and home markets.

Read More

Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has an aggressive clinical trial program set to begin in the final quarter this year and first quarter of 2018 to prove the efficacy and safety of at least three therapeutic cannabis products.

Read More

Klox focused on oral care launch, partner for wound care

Klox focused on oral care launch, partner for wound care

With franchises in dermatology, wound care and oral health, closely-held Klox Technologies has three near-term milestones this year: launching its oral care business with Colgate Palmolive; expanding the Dermatology franchise; and seeking a marketing partner for its wound business care.

Read More

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He was a co-founder of Bedrocan Canada, one of Canada’s first licensed producers of medical cannabis, and founding chairman of the Cannabis Canada Association, a trade group with 17 licensed producers. Mr. Wayne also was instrumental in developing the Canadian Consortium for the Investigation of Cannabinoids, a global innovator in education and research on medical cannabis. In this interview with BioTuesdays.com, Mr. Wayne discusses the potential of cannabis-based treatments and how they can offer alternatives to traditional medicines, avoid negative side effects and be disruptive to the pharmaceuticals sector.

Read More

Medicenna targeting brain cancer with molecular Trojan horse

Medicenna targeting brain cancer with molecular Trojan horse

Medicenna Therapeutics (TSXV:MDNA) is advancing a targeted dual-action immunotherapeutic, MDNA55, that consists of an engineered version of interleukin-4 (IL-4) plus a tumor-killing cytotoxin for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.

Read More

In conversation with Thomas Ronk of Buyins.net

In conversation with Thomas Ronk of Buyins.net

As the founder and CEO of Buyins.net, Thomas Ronk has created a proprietary database and trading strategy based on short sale timing and sales data that was not accessible to anyone prior to January 2005. As a registered representative of Transamerica Financial Resources, a division of Transamerica, Mr. Ronk managed more than $150-million in equity accounts from 1993 until 1998. He has 27 years of trading experience and is the principal of Century Pacific Investments, a registered investment advisor in California. Prior to the investment business, Mr. Ronk studied Electrical Engineering and Computer Science at the University of California at San Diego. In this interview with BioTuesdays, Mr. Ronk discusses manipulative short selling and how his company helps clients to analyze and develop a plan to deal with it.

Read More

IntelGenx has multi-faceted BD approach for its oral films

IntelGenx has multi-faceted BD approach for its oral films

With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing opportunities, and continuing to build its product pipeline jointly with R&D.

Read More

​​​​​​​In conversation with Yijun Huang

​​​​​​​In conversation with Yijun Huang

As a co-founder and chief technical officer of closely held EyeKor, which helps clients navigate the ever-changing landscape of ophthalmic clinical trials, Dr. Yijun Huang, a bioengineering executive, cut his teeth developing software and hardware solutions for ophthalmic imaging applications, both in academic and industrial situations. They include VP of engineering at Topcon Medical Systems, a major Japanese manufacturer of ophthalmic devices. He was also a member of Fundus Photograph Reading Center at the University of Wisconsin-Madison, which acts as a central imaging lab collecting and interpreting images from various ophthalmic clinical trials. In this interview with BioTuesdays.com, Dr. Huang discusses EyeKor’s Excelsior software platform for imaging data management, its market penetration and a recent collaboration with Clearside Biomedical (NASDAQ:CLSD).

Read More

3DS’ genomic imaging for precision medicine

3DS’ genomic imaging for precision medicine

As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging software, known as TeloView, goes beyond identifying whether a patient suffers from a specific condition. By analyzing a patient’s chromosomal arrangement, or signature, TeloView can help doctors tailor personalized treatment and manage each individual patient. With two decades of executive life sciences management and start-up experience, including successive roles at Bayer and J&J, Mr. Flowerday’s mission at 3DS is to transform a highly promising platform technology into a commercial reality with U.S. partners, focus on those tests that can deliver early value and broaden the company’s development program. In this interview with BioTuesdays.com, Mr. Flowerday discusses recent advances in 3DS’ lead diagnostic programs and their application to drug development.

Read More

Titan’s next ProNeura-based implant dovetails with PD awareness month

Titan’s next ProNeura-based implant dovetails with PD awareness month

After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to develop an implant to treat Parkinson’s disease.

Read More

Checkpoint targeting registration studies by end of 2018

Checkpoint targeting registration studies by end of 2018

Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and lead immuno-oncology (IO) agent, CK-301.

Read More

Histogenics to complete Phase 3 enrollment in Q2

Histogenics to complete Phase 3 enrollment in Q2

Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee cartilage regeneration.

Read More